Table 3.
Quality of Warfarin-Associated INR Monitoring and Time in INR Therapeutic Range
| eGFR Group | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| >=120 | 105–119 | 90–104 | 60–89 | 45–59 | 30–44 | 15–29 | <15 | Dialysis | Total | p-value | |
| Mean INR Monitoring Rate | |||||||||||
|
|
|||||||||||
| Full Cohort | 84.5% (n=147) | 86.5% (n=1193) | 86.4% (n=8198) | 85.8% (n=35473) | 85.6% (n=14577) | 85.7% (n=6652) | 86.2% (n=1786) | 85.0% (n=267) | 86.6% (n=334) | 85.8% (n=68627) | 0.2 |
| Heart Failure | 86.3% (n=24) | 84.3% (n=152) | 86.6% (n=966) | 86.6% (n=4768) | 86.4% (n=2801) | 86.2% (n=1844) | 87.0% (n=604) | 86.2% (n=84) | 86.4% (n=153) | 86.5% (n=11369) | 0.96 |
| No Heart Failure | 84.2% (n=123) | 86.9% (n=1041) | 86.4% (n=7232) | 85.7% (n=30705) | 85.4% (n=11776) | 85.5% (n=4808) | 85.8% (n=1182) | 84.4% (n=183) | 86.8% (n=181) | 85.7% (n=57231) | 0.06 |
| Age < 75 | 84.5% (n=147) | 86.4% (n=1173) | 86.5% (n=7727) | 86.0% (n=21873) | 86.4% (n=6272) | 86.4% (n=2225) | 86.5% (n=660) | 84.4% (n=150) | 85.5% (n=254) | 86.2% (n=40481) | 0.67 |
| Age ≥ 75 | 0 | 92.2% (n=20) | 85.7% (n=471) | 85.5% (n=13600) | 85.0% (n=8305) | 85.4% (n=4427) | 86.0% (n=1126) | 85.7% (n=117) | 90.2% (n=80) | 85.4% (n=28146) | 0.26 |
|
| |||||||||||
| Mean Overall TTR | |||||||||||
|
|
|||||||||||
| Full Cohort | 49.9% (n=127) | 52.1% (n=1077) | 57.4% (n=7215) | 60.1% (n=29753) | 59.4% (n=11854) | 57.5% (n=5377) | 54.2% (n=1442) | 51.3% (n=203) | 42.4% (n=289) | 58.9% (n=57337) | <0.001 |
| Heart Failure | 46.2% (n=23) | 52.7% (n=139) | 55.1% (n=860) | 57.0% (n=4152) | 55.9% (n=2379) | 55.7% (n=1563) | 52.5% (n=523) | 47.9% (n=66) | 40.0% (n=127) | 55.8% (n=9832) | <0.001 |
| No Heart Failure | 50.7% (n=104) | 52.0% (n=938) | 57.4% (n=6355) | 60.1% (n=25601) | 59.4% (n=9475) | 57.5% (n=3814) | 54.2% (n=919) | 51.3% (n=137) | 42.4% (n=162) | 59.6% (n=47505) | <0.001 |
| Age < 75 | 50.0% (n=127) | 52.0% (n=1059) | 57.3% (n=6828) | 59.8% (n=19075) | 58.4% (n=5404) | 55.2% (n=1906) | 53.6% (n=576) | 50.6% (n=112) | 42.1% (n=219) | 58.4% (n=35306) | <0.001 |
| Age ≥ 75 | 0 | 59.4% (n=18) | 58.4% (n=387) | 60.6% (n=10678) | 60.1% (n=6450) | 58.7% (n=3471) | 54.6% (n=866) | 52.3% (n=91) | 43.4% (n=70) | 59.8% (n=22031) | <0.001 |
|
| |||||||||||
| % of patients with Overall TTR >=60% | |||||||||||
|
| |||||||||||
| Full Cohort | 29.9% (n=38) | 38.4% (n=413) | 50.1% (n=3613) | 54.8% (n=16310) | 53.0% (n=6287) | 48.3% (n=2595) | 42.5% (n=613) | 38.4% (n=78) | 21.1% (n=61) | 24.4% (n=30008) | <0.001 |
| Heart Failure | 30.4% (n=7) | 36.7% (n=51) | 45.7% (n=393) | 48.6% (n=2018) | 45.1% (n=1072) | 44.5% (n=696) | 39.2% (n=205) | 30.3% (n=20) | 18.9% (n=24) | 45.6% (n=4486) | <0.001 |
| No Heart Failure | 29.8% (n=31) | 38.6% (n=362) | 50.7% (n=3220) | 55.8% (n=14292) | 55.0% (n=5215) | 49.8% (n=1899) | 44.4% (n=408) | 42.3% (n=52) | 22.8% (n=37) | 53.7% (n=25522) | <0.001 |
| Age < 75 | 29.9% (n=38) | 38.1% (n=403) | 49.9% (n=3410) | 54.1% (n=10322) | 51.5% (n=2781) | 43.8% (n=834) | 41.5% (n=239) | 39.3% (n=44) | 21.0% (n=46) | 51.3% (n=18117) | <0.001 |
| Age ≥ 75 | 0 | 55.6% (n=10) | 52.5% (n=203) | 56.1% (n=5988) | 54.4% (n=3506) | 50.7% (n=1761) | 43.2% (n=374) | 37.4% (n=34) | 21.4% (n=15) | 54.0% (n=11891) | <0.001 |